Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment

1. NICE Recommendation: The UK's National Institute for Health and Care Excellence (NICE) has recommended Almirall's Ebglyss (lebrikizumab) for treating moderate to severe atopic dermatitis in eligible adolescents and adults in NHS England.
2. Eligibility: Patients over 12 years old who have not responded to or cannot take systemic immunosuppressants will be eligible for the therapy.
3. Treatment Mechanism: Ebglyss works by inhibiting interleukin-13 (IL-13) signalling, which plays a key role in inflammation and the type-2 inflammatory loop in the skin.
4. Market Impact: Ebglyss is forecast to reach blockbuster status by 2026, with predicted global sales of nearly $3.4 billion by 2030.
5. Competitive Landscape: Ebglyss joins other biological therapies like Sanofi/Regeneron's Dupixent and Leo Pharma's Adbry, as well as JAK inhibitors like Pfizer's Cibinqo, Eli Lilly's Olumiant, and AbbVie's Rinvoq, in the atopic dermatitis treatment market.